Tröskelvärdet – värdet av hälsa och nytta i prissättning av nya innovativa läkemedel

Ulf Persson
Additional contact information
Ulf Persson: IHE - The Swedish Institute for Health Economics

No 2026:6, IHE Report / IHE Rapport from IHE - The Swedish Institute for Health Economics

Abstract: Cost-effectiveness analysis involves calculating the incremental cost per quality-adjusted life year (QALY) gained. The maximum acceptable cost per QALY is commonly referred to as the threshold value. The threshold value thus provides an indication of what is considered acceptable by the authority or organization responsible for assessing the value of the new medical technology.

This report provides an overview of the threshold value, what it is, how it can be estimated, and the questions it is intended to answer. The threshold value is closely linked to the principles of value-based pricing (VBP) that we use in Sweden.

The report proposes raising the TLV’s threshold values from an average of approximately 870,000 SEK to 1.3 million SEK for innovative patented medicines.

Keywords: QALY; threshold value; value based pricing; tröskelvärde; värde av hälsa; Preferenser och värdering.Preferences and valuation; metod; method; Ekonomisk utvärdering; Economic evaluation (search for similar items in EconPapers)
Pages: 64 pages
Date: 2026
Note: The report is written in Swedish with a summary in English
References: Add references at CitEc
Citations:

Downloads: (external link)
https://ihe.se/app/uploads/2026/06/IHE-RAPPORT-2026_6_.pdf Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hhs:ihewps:2026_006

Access Statistics for this paper

More papers in IHE Report / IHE Rapport from IHE - The Swedish Institute for Health Economics
Bibliographic data for series maintained by Annette Persson Dietmann ().